

STROBE Statement

| | Item No | Recommendation | Location |
|------------------------------|------------|--|----------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Title and Abstract, par. 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract, par. 2 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Introduction, par. 3-6 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction, par. 6 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | Methods, par. 3,4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods, par. 2,7 |
| Participants | 6 | Give the eligibility criteria, and the sources and methods of selection of participants. | Methods, par. 3,7 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods, par. 9 |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods, par. 4,9 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods, par. 11,12 |
| Study size | 10 | Explain how the study size was arrived at | Methods, par. 2 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Methods, par. 9 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | Methods, par. 9 |
| | | (b) Describe any methods used to examine subgroups and interactions | Methods, par. 9 |
| | | (c) Explain how missing data were addressed | n/a |
| | | (d) If applicable, describe analytical methods taking account of sampling strategy | Methods, par. 8 |
| | | (e) Describe any sensitivity analyses | Methods, par. 12 |

| Results | | | |
|--------------------------|----|--|----------------------|
| Participants | 13 | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Results, par. 1,2 |
| | | (b) Give reasons for non-participation at each stage | n/a |
| | | (c) Consider use of a flow diagram | n/a |
| Descriptive data | 14 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Results, par. 1,2 |
| | | (b) Indicate number of participants with missing data for each variable of interest | n/a |
| Outcome data | 15 | Report numbers of outcome events or summary measures over time | Results, par. 2 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Results, par. 3 |
| | | (b) Report category boundaries when continuous variables were categorized | n/a |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | n/a |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Results, par. 5,6 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Discussion, par. 1 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion, par. 5,6 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion, par. 2-4 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussion, par. 5,6 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Funding section |